CGCCanopy Growth Corporation
What is the market doing?
In a downtrend (−19% vs 200-day). That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 30). Price is −19% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CGC is trading
Canopy Growth Corporation is −42% over the past year while the S&P 500 is +18%: 60 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −19%
vs 200-day average · a clear downtrend
- RSI (14)
- 30
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 56%
Below its 52-week high
Details›
- Last close2026-10-08
- $0.85
- 1 monthS&P 500 +1.6%
- −12%
- 1 yearS&P 500 +18%
- −42%
- 5 yearsS&P 500 +86%
- −99%
- vs 50-day average$0.96
- −12%
- 52-week high
- $1.92
- 52-week low
- $0.85
- Annualised volatility
- 98%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$238K
| Year | Return |
|---|---|
| 2026 (year to date) | −26% |
| 2025 | −58% |
| 2024 | −46% |
| 2023 | −78% |
| 2022 | −74% |
| 2021 | −65% |
| 2020 | +17% |
| 2019 | −22% |
| 2018 | +14% |
| 2017 | +247% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +15% |
| Feb | 10 | 2 of 10 | −13% |
| Mar | 10 | 3 of 10 | +7.3% |
| Apr | 10 | 5 of 10 | +7.5% |
| May | 10 | 2 of 10 | −11% |
| Jun | 10 | 3 of 10 | −14% |
| Jul | 11 | 5 of 11 | +1.2% |
| Aug | 11 | 6 of 11 | +14% |
| Sep | 11 | 4 of 11 | −2.4% |
| Oct | 11 | 4 of 11 | +6.7% |
| Nov | 10 | 3 of 10 | +9.1% |
| Dec | 10 | 2 of 10 | −7.3% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #29 of 41 by RyuScore